Hardman Research

Hardman & Co

Inland Homes plc INL:DNA (interim results)

Deoxyribonucleic acid is a thread-like chain of nucleotides carrying the genetic instructions used in growth and development. In essence, it stores bio information and the DNA backbone is resistant to

Hardman & Co

Alliance Pharma Entering the US market

Alliance Pharma Plc (LON:APH) is continuing with its buy-and-build strategy having evolved through 35 acquisitions over a period of 20 years into a profitable, cash-generative, specialty pharma business. The company

Hardman & Co

Advanced Oncotherapy Confidence greatly boosted

Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in

Hardman & Co

Allergy Therapeutics Growth in a tough market

Allergy Therapeutics (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite

Hardman & Co

Avacta Group Affimer Drug Conjugates a reality

Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology

Hardman & Co

Advanced Oncotherapy Consolidating market

Advanced Oncotherapy Plc (LON:AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in